Effects of Angiotensin Converting Angiotensin Receptor Blockade Nationwide Data Survey and

Abstract: Long-term benefit of using a renin–angiotensin–aldoster-one system blocker such as an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) for patients already receiving dialysis remains undetermined. The aim of this study is to assess the efficacy and safety of ACEI or ARB use in dialysis patients. We performed a population-based cohort study with time-to-event analyses to estimate the relation between the use of ACEI/ARB and their outcomes. We used a nationwide database (Registry for Cata-strophic Il of all patie patients ag 1997 and and nonus propensity models to and CV e patients, comparab The morta ACEI/AR group an